|
1
|
Elwood PC, Gallagher AM, Duthie GG, Mur LA
and Morgan G: Aspirin, salicylates and cancer. Lancet.
373:1301–1309. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rothwell PM, Price JF, Fowkes FG, et al:
Short-term effects of daily aspirin on cancer incidence, mortality
and non-vascular death: analysis of the time course of risks and
benefits in 51 randomised controlled trials. Lancet. 379:1602–1612.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rothwell PM, Wilson M, Price JF, et al:
Effect of daily aspirin on risk of cancer metastasis: a study of
incident cancers during randomised controlled trials. Lancet.
379:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng KW, Mattheolabakis G, Wong CC, et
al: Topical phospho-sulindac (OXT-328) is effective in the
treatment of non-melanoma skin cancer. Int J Oncol. 41:1199–1203.
2012.PubMed/NCBI
|
|
5
|
Huang L, Mackenzie GG, Sun Y, et al:
Chemotherapeutic properties of phospho-nonsteroidal
anti-inflammatory drugs, a new class of anticancer compounds.
Cancer Res. 71:7617–7627. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mackenzie GG, Ouyang N, Xie G, et al:
Phospho-sulindac (OXT-328) combined with difluoromethylornithine
prevents colon cancer in mice. Cancer Prev Res. 4:1052–1060. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu C, Cheng KW, Ouyang N, et al:
Phosphosulindac (OXT-328) selectively targets breast cancer stem
cells in vitro and in human breast cancer xenografts. Stem Cells.
30:2065–2075. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu R, Cheng KW, Mackenzie G, et al:
Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer
xenografts in mice: enhanced efficacy and mitochondria targeting by
its formulation in solid lipid nanoparticles. Pharm Res.
29:3090–3101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hanif R, Qiao L, Shiff SJ and Rigas B:
Curcumin, a natural plant phenolic food additive, inhibits cell
proliferation and induces cell cycle changes in colon
adenocarcinoma cell lines by a prostaglandin-independent pathway. J
Lab Clin Med. 130:576–584. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kawamori T, Lubet R, Steele VE, et al:
Chemopreventive effect of curcumin, a naturally occurring
anti-inflammatory agent, during the promotion/progression stages of
colon cancer. Cancer Res. 59:597–601. 1999.PubMed/NCBI
|
|
11
|
Villegas I, Sanchez-Fidalgo S and de la
Lastra CA: Chemopreventive effect of dietary curcumin on
inflammation-induced colorectal carcinogenesis in mice. Mol Nutr
Food Res. 55:259–267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Su CC, Yang JS, Lu CC, et al: Curcumin
inhibits human lung large cell carcinoma cancer tumour growth in a
murine xenograft model. Phytother Res. 24:189–192. 2010.PubMed/NCBI
|
|
13
|
Dance-Barnes ST, Kock ND, Moore JE, et al:
Lung tumor promotion by curcumin. Carcinogenesis. 30:1016–1023.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giladi N, Kazanov D, Shpitz B, Aroch I,
Kraus S and Arber N: Curcumin potentiates the pro-apoptotic effects
of sulindac sulfone in colorectal cancer. Expert Opin Investig
Drugs. 19:S117–S124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee JY, Lee YM, Chang GC, et al: Curcumin
induces EGFR degradation in lung adenocarcinoma and modulates p38
activation in intestine: the versatile adjuvant for gefitinib
therapy. PloS One. 6:e237562011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yin H, Guo R, Xu Y, et al: Synergistic
antitumor efficiency of docetaxel and curcumin against lung cancer.
Acta Biochim Biophys Sin. 44:147–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ganta S and Amiji M: Coadministration of
Paclitaxel and curcumin in nanoemulsion formulations to overcome
multidrug resistance in tumor cells. Mol Pharm. 6:928–939. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sung B, Kunnumakkara AB, Sethi G, et al:
Curcumin circumvents chemoresistance in vitro and potentiates the
effect of thalidomide and bortezomib against human multiple myeloma
in nude mice model. Mol Cancer Ther. 8:959–970. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Francois G and Katz JL: Nanoparticles and
nanocapsules created using the Ouzo effect: spontaneous
emulisification as an alternative to ultrasonic and high-shear
devices. Chemphyschem. 6:209–216. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Galindo-Rodriguez S, Allemann E, Fessi H
and Doelker E: Physicochemical parameters associated with
nanoparticle formation in the salting-out, emulsification-diffusion
and nanoprecipitation methods. Pharm Res. 21:1428–1439. 2004.
View Article : Google Scholar
|
|
21
|
Wong CC, Cheng KW, Xie G, et al:
Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal
anti-inflammatory drugs: relevance to their pharmacological
activity. J Pharmacol Exp Ther. 340:422–432. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Balimane PV, Han YH and Chong S: Current
industrial practices of assessing permeability and P-glycoprotein
interaction. AAPS J. 8:E1–E13. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie G, Nie T, Mackenzie GG, et al: The
metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and
the effect of difluoromethylornithine. Br J Pharmacol.
165:2152–2166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chearwae W, Anuchapreeda S, Nandigama K,
Ambudkar SV and Limtrakul P: Biochemical mechanism of modulation of
human P-glycoprotein (ABCB1) by curcumin I, II and III purified
from Turmeric powder. Biochem Pharmacol. 68:2043–2052. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shukla S, Zaher H, Hartz A, et al:
Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug
resistance-linked ABC drug transporter in mice. Pharm Res.
26:480–487. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wortelboer HM, Usta M, van der Velde AE,
et al: Interplay between MRP inhibition and metabolism of MRP
inhibitors: the case of curcumin. Chem Res Toxicol. 16:1642–1651.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wortelboer HM, Usta M, van Zanden JJ, et
al: Inhibition of multidrug resistance proteins MRP1 and MRP2 by a
series of alpha,beta-unsaturated carbonyl compounds. Biochem
Pharmacol. 69:1879–1890. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Y, Revalde JL, Reid G and Paxton JW:
Modulatory effects of curcumin on multi-drug resistance-associated
protein 5 in pancreatic cancer cells. Cancer Chemother Pharmacol.
68:603–610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rigas B and Shiff SJ: Nonsteroidal
anti-inflammatory drugs (NSAIDs), cyclooxygenases and the cell
cycle. Their interactions in colon cancer. Adv Exp Med Biol.
470:119–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
